Joel Embiid's recurring health issues have reignited debates around the NBA's MVP award and player participation criteria. Embiid's recent absence from a highly anticipated game has highlighted the growing concern over how player availability affects the league's award races. With Embiid having missed 11 games and on track to miss a total of 21, which would leave him playing only 61 games in the season, questions arise about his eligibility for awards such as All-NBA, MVP, and Defensive Player of the Year. The discussion is intensified by the contrast with players like Jokic and SGA, who have each only missed one game, making Embiid's ability to provide comparable value in fewer games a contentious point, as he is expected to play only 63 games compared to their likely 77.
Joel Embiid has missed 11 games this season and is on pace to play 61 games this season. That means he wouldn’t qualify for All-NBA, MVP, DPoY etc. Jimmy Butler, Tyrese Haliburton, Porzingis, Bam, all running on thin margins too. https://t.co/UEiGZOdAXv
The thing about the 65 game rule for MVP is that unless something changes, the games played gap between Embiid and Jokic/SGA is going to be massive, both of those guys have only missed one game. Almost impossible to provide more value in 63 games than those guys do in like 77.
The thing about the 65 game rule for MVP is that unless something changes, the games played game between Embiid and Jokic/SGA is going to be massive, both of those guys have only missed one game. Almost impossible to provide more value in 63 games than those guys do in like 77.
From @TheAthletic: Joel Embiid's late scratch robbed fans of a matchup between the NBA's two best players over the last three seasons. Now, player participation, the MVP race and the league's awards criteria are back under the microscope. https://t.co/sNREHTroP6
Yet again, Joel Embiid’s health is getting in the way of the kind of greatness the NBA has rarely seen. And now, the debate about this season’s MVP award and player participation grows even more interesting. Our writers discuss ⤵️ https://t.co/jNusPg4nBS https://t.co/M0VBpnzAZ7